Goosehead Insurance, Inc
GSHD · NASDAQ
Analyst ratings
buy · 11 ratings
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| July 15, 2026 | Piper Sandler | Maintains | Overweight | $72.00 |
| July 13, 2026 | JP Morgan | Maintains | Neutral | $60.00 |
| July 13, 2026 | RBC Capital | Maintains | Sector Perform | $55.00 |
| July 9, 2026 | Cantor Fitzgerald | Maintains | Overweight | $76.00 |
| July 8, 2026 | UBS | Maintains | Buy | $70.00 |
| June 9, 2026 | UBS | Maintains | Buy | $67.00 |
| May 26, 2026 | Piper Sandler | Maintains | Overweight | $52.00 |
| May 14, 2026 | JP Morgan | Maintains | Neutral | $55.00 |
| April 27, 2026 | UBS | Maintains | Buy | $85.00 |
| April 23, 2026 | RBC Capital | Maintains | Sector Perform | $52.00 |
| April 23, 2026 | Piper Sandler | Maintains | Overweight | $60.00 |
| April 23, 2026 | Keefe, Bruyette & Woods | Maintains | Outperform | $80.00 |
| April 14, 2026 | B of A Securities | Maintains | Underperform | $37.00 |
| April 13, 2026 | Citizens | Maintains | Market Outperform | $100.00 |
| April 9, 2026 | JP Morgan | Maintains | Neutral | $58.00 |
| April 9, 2026 | Cantor Fitzgerald | Maintains | Overweight | $67.00 |
| April 8, 2026 | UBS | Maintains | Buy | $81.00 |
| April 7, 2026 | Keefe, Bruyette & Woods | Maintains | Outperform | $75.00 |
| February 23, 2026 | UBS | Maintains | Buy | $90.00 |
| February 23, 2026 | JP Morgan | Maintains | Neutral | $68.00 |
| February 18, 2026 | BMO Capital | Maintains | Market Perform | $55.00 |
| February 18, 2026 | Truist Securities | Maintains | Hold | $58.00 |
| February 18, 2026 | Citizens | Maintains | Market Outperform | $125.00 |
| February 18, 2026 | Keefe, Bruyette & Woods | Maintains | Outperform | $85.00 |
| February 18, 2026 | Piper Sandler | Upgrades | Overweight | $69.00 |
| January 14, 2026 | Cantor Fitzgerald | Maintains | Overweight | $111.00 |
| January 7, 2026 | JP Morgan | Maintains | Neutral | $80.00 |
| November 25, 2025 | BMO Capital | Maintains | Market Perform | $79.00 |
| October 27, 2025 | UBS | Maintains | Buy | $121.00 |
| October 23, 2025 | Truist Securities | Maintains | Hold | $72.00 |
| October 23, 2025 | Keefe, Bruyette & Woods | Maintains | Outperform | $95.00 |
| October 23, 2025 | Piper Sandler | Maintains | Neutral | $69.00 |
| October 14, 2025 | JMP Securities | Maintains | Market Outperform | $140.00 |
| October 9, 2025 | JP Morgan | Maintains | Neutral | $85.00 |
| October 8, 2025 | UBS | Maintains | Buy | $130.00 |
| October 6, 2025 | Piper Sandler | Maintains | Neutral | $79.00 |
| September 23, 2025 | Truist Securities | Maintains | Hold | $85.00 |
| September 2, 2025 | Piper Sandler | Maintains | Neutral | $92.00 |
Revenue growth trajectory and financial performance sustainability
New business commissions grew 29% in Q1 2026 — the fastest pace in nearly five years — and management reiterated full-year guidance of 10% to 19% total revenue growth, with acceleration expected in the second half as client retention improvements flow through. The underlying business momentum suggests a compelling recovery.
Despite earnings beating estimates, Q1 2026 revenue of $79.48 million came in significantly below analyst expectations of $105.16 million. Bank of America maintained an underperform rating with a reduced price target of $37, reflecting skepticism about whether reported growth translates into consistent top-line delivery.
AI strategy and technology transformation under new CTO Eben Hewitt
The appointment of Eben Hewitt as CTO signals a concrete near-term catalyst around AI and Digital Agent 2.0 execution. The most optimistic analysts model revenue reaching $696 million by 2029, assuming Goosehead's AI marketplace materially reshapes margins and market share well above baseline projections.
Hewitt's appointment does not materially change the core risk: whether Goosehead can defend its independent-agent model against digital disintermediation. The AI narrative alone is insufficient, as the company's removal from the S&P Insurance Select Industry Index weighs on sentiment for a stock already experiencing weak multi-year returns.
Stock valuation and price target divergence amid steep share price decline
With GSHD down 58% over the last 12 months despite 16.2% revenue growth, several analysts see deep undervaluation. Keefe, Bruyette & Woods rates the stock outperform with an $80 target, UBS maintains a Buy with a $70 target, and a discounted model projects a 110.2% total return to $91.22 by December 2028.
JPMorgan and Royal Bank of Canada both maintain neutral or sector perform ratings, with price targets of $60 and $55 respectively — well below the consensus average. The stock's historical P/E compression and elevated short interest of over 11% suggest significant investor skepticism about a near-term re-rating.